Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Text availability
Article attribute
Article type
Publication date

Search Results

231 results
Filters applied: . Clear all Results are displayed in a computed author sort order. Results by year timeline is unavailable
Page 1
ERK2, but not ERK1, mediates acquired and "de novo" resistance to imatinib mesylate: implication for CML therapy.
Aceves-Luquero CI, Agarwal A, Callejas-Valera JL, Arias-González L, Esparís-Ogando A, del Peso Ovalle L, Bellón-Echeverria I, de la Cruz-Morcillo MA, Galán Moya EM, Moreno Gimeno I, Gómez JC, Deininger MW, Pandiella A, Sánchez Prieto R. Aceves-Luquero CI, et al. Among authors: pandiella a. PLoS One. 2009 Jul 1;4(7):e6124. doi: 10.1371/journal.pone.0006124. PLoS One. 2009. PMID: 19568437 Free PMC article.
Personalized therapies in the cancer "omics" era.
Ocaña A, Pandiella A. Ocaña A, et al. Among authors: pandiella a. Mol Cancer. 2010 Jul 29;9:202. doi: 10.1186/1476-4598-9-202. Mol Cancer. 2010. PMID: 20670437 Free PMC article. Review.
231 results
You have reached the last page of results. A maximum of 10,000 results are available.
Jump to page